Antibacterial susceptibility patterns and cross-resistance of acinetobacter, isolated from hospitalized patients, Southern Iran

Iranian Red Crescent Medical Journal

Volumn 13, Issue 11, 2011, Pages 832-836

  Japoni, S ^a   Farshad, S ^b   Ali, A Abdi ^a   Japoni, A ^b  

^a ALZAHRA UNIVERSITY   (Iran)

^b SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Acinetobacter; Antibiotic resistance; Cross resistance; Iran

Indexed keywords

AMIKACIN; ANTIBIOTIC AGENT; CEFEPIME; CEFTAZIDIME; CIPROFLOXACIN; COLISTIN; GENTAMICIN; IMIPENEM; MEROPENEM; NORFLOXACIN; SULPERAZON; SULTAMICILLIN; TOBRAMYCIN;

ACINETOBACTER; ACINETOBACTER BAUMANNII; ACINETOBACTER HAEMOLYTICUS; ACINETOBACTER LWOFFII; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATION; CROSS RESISTANCE; EPSILOMETER TEST; FEMALE; HOSPITAL PATIENT; HUMAN; IRAN; MALE; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NONHUMAN; SPECIES IDENTIFICATION;

EID: 84856420691     PISSN: 20741804     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Dijkshoorn L, van Aken E, Shunburne L, van der Reijden TJ, Bernards AT, Nemec A, Towner KJ. Prevalence of Acinetobacter baumannii and other Acinetobacter spp. in faucal samples from non-hospitalized individuals. Clin Microbiol Infect 2005;11: 329-32. [15760432] [http://dx.doi.org/10.1111/j.1469-0691.2005.01093.x]
2. Agodi A, Zarrilli R, Barchitta M, Anzaldi A, Di Popolo A, Mattaliano A, Ghiraldi E, Travali S. Alert surveillance of intensive care unit acquired Acinetobacter infections in a Sicilian hospital. Clin Microbiol Infect 2006;12:241-247. [16451411] [http://dx.doi.org/10.1111/j.1469-0691.2005.01339.x]
3. Mahgoub S, Ahmed J, Glatt AE. Completely resistant Acinetobacter baumannii strains. Infect Control Hosp Epidemiol 2002;23:477-479. [12186218] [http://dx.doi.org/10.1086/502091]
4. Levin AS. Multi-resistant Acinetobacter infections: a role for sulbactam combinations in overcoming an emerging worldwide problem. Clin Microbiol Infect 2002;8:144-153. [12010169] [http://dx.doi.org/10.1046/j.1469-0691.2002.00415.x]
5. Villegas MV, Hartstein AI. Acinetobacter outbreaks, 1977-2000. Infect Control Hosp Epidemiol 2003;24: 284-295.[12725359] [http://dx.doi.org/10.1086/502205]
6. Baumann P. Isolation of Acinetobacter from soil and water. J Bacterial 1968;96:39-42.
7. Bouvet PJM, Grimond PAD. Taxonomy of the genus Acinetobacter with the recognition of Acinetobacter Baumannii sp. nov., Acinetobacter haemolyticus sp. nov., Acinetobacter Johnsonii sp. nov. and emended description of Acinetobacter calcoaceticus and Acinetobacter lwoffii. Int J Syst Bacteriol 1986;36:228-240. [http://dx.doi.org/10.1099/00207713-36-2-228]
8. Johnson JL, Anderson RS, Ordal EJ. Nucleic acid homologies, among oxidase- negative moraxella species. J Bacterial 1970;101:568-573. [5413826]
9. Feizabadi MM, Fathollahzadeh B, Taherikalani M, Rasoolinejad M, Sadeghifard N, Aligholi M, Soroush S, Mohammadi-Yegane S. Antimicrobial susceptibility patterns and distribution of bla OXA genes among Acinetobacter Spp. isolated from patients at Tehran hospitals. Jpn J Infect Dis 2008;61:274-278. [18653968]
10. Seifert H, Baginski R, Schulze A, Pulverer G. The distribution of Acinetobacter species in clinical culture materials. Zentralbl Bakteriol 1993;279:544-552. [8305812]
11. Gisneous JM, Rodriguez-Bano J. Nosocomial bacteremia due to Acinetobacter baumannii: epidemiology, clinical features and treatment. Clin Micobiol Infects 2002;8:687-693. [12445005] [http://dx.doi.org/10.1046/j.1469-0691.2002.00487.x]
12. Gales AC, Reis AO, Jones RN. Contemporary assessment of antimicrobial susceptibility testing methods for polymyxin B and Colistin: review of available interpretative criteria and quality control guidelines. J Clin Microbiol 2001;39:183-190. [11136768] [http://dx.doi.org/10.1128/JCM.39.1.183-190.2001]
13. Davis KA, Moran KA, McAllister K, Gray PJ. Multi-drug resistant Acinetobacter extremity infections in soldiers. Emerg Infect Dis 2005;11: 1218-1224. [16102310]
14. Katsaragakis S, Markogiannakis A, Toutouzas KG, Drimousis P, Larentzakis A, Theodoraki, EM, Theodorou D. Acinetobacter baumannii infections in a surgical intensive care unit: predictors of multi-drug resistance. World J Sury 2008;32: 1194-1202. [18408967] [http://dx.doi.org/10.1007/s00268-008-9571-3]
15. Reynolds R, Potz N, Colman M, Williams A, Livermore D, Macgowan A. Antimicrobial susceptibility of the pathogens of bacteraemia in the UK and Ireland 2001-2002: the BSAC Bacteremia Resistance surveillance programme. J Antimicrob Chemother 2004;53:1018-1032. [15128723] [http://dx.doi.org/10.1093/jac/dkh232]
16. Streit JM, Jones RN, Sader HS, Fritsche TR. Assessment of pathogen occurrences and resistance profiles among infected patients in the intensive care unit: report from SENTRY antimicrobial surveillance program (North America, 2001). Int J Antimicrob Agents 2004;24:111-118. [15288308] [http://dx.doi.org/10.1016/j.ijantimicag.2003.12.019]
17. Tognim MCB, Andrade SS, Silbert D, Gales AC, Jones RN, Sader HS. Resistance trends of Acinetobacter spp. In Latin America and characterization of international dissemination of multi-drug resistant strains: five year report of the SENTRY antimicrobial surveillance program. Int J Infect Dis 2004;8:284-291. [15325597] [http://dx.doi.org/10.1016/j.ijid.2003.11.009]
18. Fagon JY, Chastre J, Hance AJ, Montravers P, Novara A, Gibert C. Nosocomial pneumonia in ventilated patients: a cohort study evaluating attributable mortality and hospital stay. Am J Med 1993;94:281-288. [8452152] [http://dx.doi.org/10.1016/0002-9343(93)90060-3]
19. Lautenbach E, Synnestvedt M, Weiner MG, Bilker WB, Vo L, Schein J, Kim M. Epidemiology and impact of imipenem resistance in Acinetobacter baumannii. Infect Control Hosp Epidemiol 2009;30: 1186-1192. [19860563] [http://dx.doi.org/10.1086/648450]
20. Reed MD, Stern RC, O'Riordan MA, Blumer JL. The pharmacokinetics of colistin in patients with cystic fibrosis. J Clin Pharmacol 2001;41:645-654. [11402633] [http://dx.doi.org/10.1177/00912700122010537]
21. Lewis JR, Lewis SA. Colistin interactions with mammalian outothelium. Am J physiol cell physiol 2004; 286:C913-C922. [14668261] [http://dx.doi.org/10.1152/ajpcell.00437.2003]
22. Perez F, Hujer AM, Hujer KM, Decker BK, Rather PN, Bonomo RA. Global Challenge of multidrugresistant Acinetobacter baumannii. Antimicrob Agents Chemother 2007; 51:3471-3484. [17646423] [http://dx.doi.org/10.1128/AAC.01464-06]
23. Turton JF, Kaufmann ME, Glover J, Coelho JM, Warner M, Pike R, Pitt TL. Detection and typing of integrons in epidemic strains of Acinetobacter baumannii found in the United Kingdom. J Clin Microbiol 2005;43:3074-3082. [16000417] [http://dx.doi.org/10.1128/JCM.43.7.3074-3082.2005]
24. Gonzalez G, Sossa K, Bello H, Dominguez M, Mella S, Zemelman R. Presence of integrons in isolates of different biotypes of Acinetobacter baumannii from Chilean hospitals. FEMS Microbiol lett 1998; 161:125-8. [9561739] [http://dx.doi.org/10.1111/j.1574-6968.1998.tb12937.x]
25. Seward RJ, Towner KJ. Detection of integrons in worldwide nosocomial isolates of Acinetobacter spp. Clin Microbiol Infect 1999;5:308-318. [11856275] [http://dx.doi.org/10.1111/j.1469-0691.1999.tb00149.x]